Podcasts about pharmaceuticals

After six births within the system—including a cesarean at 37 weeks due to partial placenta previa and subsequent hospital abuse—Ashleigh knew she was done.Now a mother of nine and a Radical Birth Keeper School graduate, Ashleigh joins me to share her accumulated wisdom from nearly twenty years of mothering and birthing. We met in person at Matriarch Rising Festival, and in this conversation, we explore what it means to truly live the lessons that birth offers us.We discuss the pros and cons of having children present during birth, what it looks like to honor our evolving faith journeys, and how Ashleigh navigated the tension between her freebirth path and her husband's discomfort with it.I also challenge Ashleigh's decision to pull away from her Christian audience, encouraging her to consider what it might mean to let her community see her more deeply. She speaks vulnerably about her own healing from rage and how she now coaches mothers who find themselves lashing out at their children—because she's been there too.Come listen, learn, and receive from a mother of nine whose story carries the depth and clarity only time, experience, and devotion can bring.✨Start Your Journey: The Complete Guide to Freebirth - Our best-selling, self-paced course for women ready to claim their births on their own terms. Enroll here.✨Donate to the podcast here. If you want to connect with Ashleigh, follow her on Instagram here. SPOTIFY/APPLE ONLY:Find more from Emilee on Instagram, YouTube and the Free Birth Society website.Disclaimer: Free Birth Society, LLC of North Carolina shares personal and educational stories and experiences related to freebirth and holistic care. This content is not medical advice, and we are not a licensed midwifery practice. Testimonials reflect individual experiences; results may vary. For services or scheduling, contact info@freebirthsociety.com. See full disclaimer at freebirthsociety.com/youtubeterms.

When the system kills a $2.4 million study on Black maternal health with one Friday afternoon email, the message is loud and clear: stop asking questions that make power uncomfortable. Dr. Jaime Slaughter-Acey, an epidemiologist at UNC, built a groundbreaking project called LIFE-2 to uncover how racism and stress shape the biology of pregnancy. It was science rooted in community, humanity, and truth. Then NIH pulled the plug, calling her work “DEI.” Jaime didn't quit. She fought back, turning her grief into art and her outrage into action. This episode is about the cost of integrity, the politics of science, and what happens when researchers refuse to stay silent.RELATED LINKS• The Guardian article• NIH Grant• Jaime's LinkedIn Post• Jaime's Website• Faculty PageFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Could studying the DNA of extinct animals – or even bringing them back to life – help us save today's endangered species and inform modern medicine?  That may sound like the premise for a Hollywood movie, but it's work that our Raise the Line guest, Dr. Beth Shapiro, is actually engaged in as Chief Science Officer at Colossal Biosciences, which describes itself as the world's first and only de-extinction company.  “It's not just about learning about the past. It's learning about the past so we have more validated scientific information that we can use to predict what we can do to better influence the future,” she tells host Michael Carrese. An internationally-renowned evolutionary molecular biologist and paleogeneticist, Dr. Shapiro is a pioneer in ancient DNA research and has successfully sequenced genomes, like that of the dodo, to study evolution and the impact on humans. At Colossal Biosciences, she leads teams working to bring back traits of extinct species such as the mammoth, not for spectacle, but to restore ecological balance. “When species become extinct, you lose really fundamental interactions between species that existed in that ecosystem. By taking a species that's alive today and editing its DNA so that it resembles those extinct species, we can functionally replace those missing ecological interactions.” Tune into this utterly fascinating conversation to hear about what Jurassic Park got wrong, the positive ecological impact of reintroducing giant tortoises to Mauritius, and the ethics of using gene editing and other biotechnologies. Mentioned in this episode:Colossal Biosciences If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

EPISODE DESCRIPTIONAllison Applebaum was supposed to become a concert pianist. She chose ballet instead. Then 9/11 hit, and she ran straight into a psych ward—on purpose. What followed was one of the most quietly revolutionary acts in modern medicine: founding the country's first mental health clinic for caregivers. Because the system had decided that if you love someone dying, you don't get care. You get to wait in the hallway.She's a clinical psychologist. A former dancer. A daughter who sat next to her dad—legendary arranger of Stand By Me—through every ER visit, hallway wait, and impossible choice. Now she's training hospitals across the country to finally treat caregivers like patients. With names. With needs. With billing codes.We talked about music, grief, psycho-oncology, the real cost of invisible labor, and why no one gives a shit about the person driving you to chemo. This one's for the ones in the waiting room.RELATED LINKSAllisonApplebaum.comStand By Me – The BookLinkedInInstagramThe Elbaum Family Center for Caregiving at Mount SinaiFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

According to the Bloomberg School of Public Health at Johns Hopkins University, women make up 70% of the global healthcare workforce but hold only about 25% of leadership positions. Our guest today on Raise the Line, Dr. Roopa Dhatt, has been a leading voice in the movement to correct that imbalance through co-founding an organization called Women in Global Health (WGH), which has established chapters in over 60 countries since it started a decade ago. Dr. Dhatt is also pursuing that agenda and addressing other pressing issues in healthcare as a Young Global Leader at the World Economic Forum. “We're changing the equation so women delivering health are also viewed and valued as leaders,” says the internal medicine physician and assistant professor at Georgetown University School of Medicine. Beyond leadership equity, Dr. Dhatt is also seeking to address systemic pay inequities and high levels of violence and harassment experienced by women in the health sector, issues that were highlighted in research conducted by WGH. Although WGH has seen high-level success influencing policy at the World Health Organization and United Nations, Dr. Dhatt says the heart of its success is local. “Women community health workers have begun to see themselves as leaders and the heroines of health in their communities. That's profound change.” Join host Michael Carrese for a probing conversation that identifies the structural barriers blocking advancement for women and that explains why the health of communities and the planet depend on inclusive leadership.Mentioned in this episode:Women in Global HealthWHO Report: Delivered By Women, Led By MenDr. Roopa Dhatt on LinkedIn If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Santhera Pharmaceuticals chief medical officer Dr Shabir Hasham talked with Proactive's Stephen Gunnion about the company's progress in launching AGAMREE, a dissociative corticosteroid for Duchenne muscular dystrophy (DMD). Santhera is a Swiss specialty pharmaceutical company focused on treatments for pediatric rare diseases. Its lead product, AGAMREE, aims to offer comparable efficacy to traditional corticosteroids while reducing the debilitating side effects often associated with long-term steroid use in DMD patients. Hasham noted that current treatments are frequently discontinued or reduced after a few years due to growth stunting, weight gain, and other complications. “Our drug AGAMREE is a corticosteroid, but we've been able to modify the structure of it… we offer the same efficacy… but we are able to avoid many of the debilitating side effects,” said Hasham. The treatment has already launched in Germany, Austria, and the UK, with further European rollouts expected in the coming months. Commercialisation in the US is underway via a partnership with Catalyst Pharmaceuticals, and entry into China has begun through Spirit Genetics. New long-term data from the Guardian study shows patients treated for up to eight years exhibited no growth stunting and significantly fewer fractures. Hasham said the data may encourage wider use in countries where steroid uptake has been low and added, “This will make a very positive impact in terms of our ability to roll the drug out.” For more interviews like this, visit Proactive's YouTube channel. Don't forget to like the video, subscribe to the channel, and turn on notifications so you never miss an update. #SantheraPharmaceuticals #AGAMREE #DuchenneMuscularDystrophy #RareDiseaseTreatment #PediatricHealth #SteroidAlternatives #PharmaNews #BiotechUpdates #HealthcareInnovation #ProactiveInvestors

Dr Reza is the Bernard M. Gordon Managing Director, Technical Leadership & Communication Programs at Massachusetts Institute of Technology MIT He  returned to MIT in 2018 after a 29-year career in the Consumer Packaged Goods, Pharmaceuticals, and Agricultural Chemical Industries. Immediately prior to MIT, Reza was the Vice-president of Research, Development, and Innovation for the Specialty Division of the Clorox Company In addition to his passion for developing leaders, Reza is passionate about workplace equality and is the Vice-Chair of the Board of Out & Equal Workplace Advocates. He and his husband James enjoy travel and hiking. he received his BSc.(Eng.) in Chemical Engineering from Imperial College, University of London, and his MSCEP in Chemical Engineering Practice and Ph.D. in Chemical Engineering from MIT. Our life journeys converged in 2022, when I got the opportunity to know him at a design thinking course at MIT, and from that moment I realized about his true passion to give, to share and teach.  Whenever I see him, he is  welcoming you with a great Smile , I love how he provokes great reflections and conversations, a great mentor, a kind and generous educator.  https://tlc.mit.edu/ https://www.mit.edu/ https://professional.mit.edu/

Een groot discussiepunt van de afgelopen verkiezingen was… de zorg. En dan met name het debat rondom de bevriezing van het basispakket. Sommige partijen wilde de stijging van de zorgkosten afremmen door de basisverzekering te bevriezen.  Dat betekent dat bepaalde nieuwe medicijnen niet automatisch in het zorgpakket worden opgenomen. Omdat de prijzen van deze medicijnen simpelweg erg duur zijn.  Maar waarom zijn ze zo duur? Dat vragen we aan  Wim Groot, hoogleraar gezondheidseconomie aan de Universiteit Maastricht en Wim Goettsch, hoogleraar Health Technology Assessment of Pharmaceuticals aan de Universiteit Utrecht en bijzonder adviseur bij het nederlands zorginstituut.

“They say it takes a village to raise a child. I really think it takes a village to treat a patient,” says Dr. Lanae Mullane, a naturopathic doctor and clinical strategist who has spent years at the forefront of bridging functional medicine, nutraceutical development, and digital health. In this episode of Raise the Line, host Lindsey Smith explores Dr. Mullane's view that naturopathic medicine complements conventional care by expanding -- not replacing -- the clinical toolkit, and that collaboration should be the future of medicine. “At the end of the day, collaboration and connection create the best outcomes for the people we serve,” she says. Their in-depth conversation also spans the shifting landscape of women's hormone health, including the perimenopausal transition and long-overdue calls for research equity. “We're not just smaller versions of men. We need to have dedicated research for us.” Tune in to learn about the importance of grounding health in sustainable habits, rethinking midlife care for women, and how to help patients take ownership of their health.Mentioned in this episode:Joi + BlokesSuppCoDr. Mullane's Clinical Website If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

In this week's episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks.com, welcomes Mike Exton, PhD, CEO of Lexicon Pharmaceuticals, for a conversation about leveraging gene science to develop innovative medicines for serious chronic conditions. Dr. Exton discusses Lexicon's growing pipeline, which includes promising therapies for diabetic peripheral neuropathic pain, hypertrophic cardiomyopathy and other cardiometabolic diseases, areas where unmet need remains high despite decades of research. He also shares insights from his extensive leadership experience across the pharmaceutical industry, including his time as Cardiometabolism Therapeutic Head at Novartis, and how those experiences are shaping his vision for Lexicon's next chapter of growth. Prior to joining Novartis, Dr. Exton was director of business development with Invida Pty Ltd and spent nine years with Eli Lilly Australia, where he held a variety of research, business development and sales positions. Dr. Exton has served as CEO and a director at Lexicon Pharmaceuticals since July 2024. Dr. Exton has a BSc and a PhD in neuroscience from the University of Newcastle and a PhD in immunology from the University of Essen, Germany. Tune in to hear how Lexicon is advancing precision-driven approaches to transform treatment outcomes in diabetes, pain management and heart disease, and how gene science continues to redefine possibilities in chronic disease therapeutics.   For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

EPISODE DESCRIPTIONRebecca V. Nellis never meant to run a nonprofit. She just never left. Twenty years later, she's still helming Cancer and Careers after a Craigslist maternity-leave temp job turned into a lifelong mission.In this 60-minute doubleheader, we cover everything from theater nerdom and improv rules for surviving bureaucracy, to hanging up on Jon Bon Jovi, to navigating cancer while working—or working while surviving cancer. Same thing.Rebecca's path is part Second City, part Prague hostel, part Upper East Side grant writer, and somehow all of that makes perfect sense. She breaks down how theater kids become nonprofit lifers, how “sample sale feminism” helped shape a cancer rights org, and how you know when the work is finally worth staying for.Also: Cleavon Little. Tap Dance Kid. 42 countries. And one extremely awkward moment involving a room full of women's handbags and one very confused Matthew.If you've ever had to hide your diagnosis to keep a job—or wanted to burn the whole HR system down—this one's for you.RELATED LINKSCancer and CareersRebecca Nellis on LinkedIn2024 Cancer and Careers Research ReportWorking with Cancer Pledge (Publicis)CEW FoundationI'm Not Rappaport – Broadway InfoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship opportunities, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

“It's kind of a miracle, frankly,” says Dr. John Buse, a distinguished professor at the University of North Carolina School of Medicine, referring to the effectiveness of GLP-1 receptor agonist medications such as Ozempic in treating type 2 diabetes, promoting significant weight loss, and reducing cardiovascular risk. As a physician scientist for the last three decades at UNC, Dr. Buse has played a key role in ushering in this new era of diabetes care, leading or participating in over 200 clinical studies on this class of drugs and others. “Nothing has impacted diabetes care like the GLP-1 receptor agonists. I have lots of patients whose diabetes was never well controlled who have seen all their metabolic problems essentially resolved.”  In this fascinating conversation with Raise the Line host Lindsey Smith, Dr. Buse not only explains how these drugs work, but also provides a clear-eyed look at side effects, and addresses issues of cost and access. Join us for the remarkable story – including the role played by Gila monsters -- behind one of the biggest developments in medicine over the past several years from a world renowned diabetes researcher and clinician. Mentioned in this episode:UNC School of Medicine If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

We love to hear from our listeners. Send us a message. On this week's episode — the last of our four-part series focused on South Florida — we catch up with Rich Daly, CEO at Catalyst Pharmaceuticals, a member of Life Science Leader's editorial advisory board and Miami-based location host for our in-person series. Rich talks about Catalyst's rare disease strategy built on operational excellence (including how to select a rare disease special pharmacy), his criteria for selecting de-risked, differentiated, and accretive products for rare diseases, partnering outside the U.S., and what new incentives Florida politicians could create to help South Florida grow even faster as a life sciences hub. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Between new developments on a rebate pilot program, discussions of possible cuts to Medicare payment for 340B drugs, and new action in states nationwide, this fall has been a jam-packed season for 340B. We sit down with 340B Health President and CEO Maureen Testoni to break down the latest.Questions Remain About January's 340B Rebate Pilot After the Health Resources & Services Administration (HRSA) released 340B rebate pilot program guidance over the summer, all nine manufacturers of the 10 drugs subject to Medicare price caps applied to HRSA to implement rebates for the drugs starting in January. Testoni says we expect to find out which plans are approved in early November, as drugmakers need to give eight weeks of notice so covered entities can prepare for the change. Testoni says questions remain about the rebate pilot, but information that the drugmakers' rebate vendor has released so far provides enough detail for hospitals to start preparing for both rebates and price caps.Potential Medicare Cuts Expected To Target 340B HospitalsEarlier this year, the Trump administration released an executive order directing the Centers for Medicare & Medicaid Services (CMS) to survey hospitals on drug acquisition costs with the goal of using the results to set payment rates for Medicare Part B drugs starting in 2027. Testoni says she is concerned the proposed survey will lead to CMS targeting only 340B drugs for cuts that could bring payment rates down to actual acquisition costs, which would be a steeper cut than what the agency imposed during the first Trump administration.States Keep Moving on Contract Pharmacy Protections, 340B MandatesNearly 20 states have contract pharmacy protection laws in place and a small number of drugmakers have sued to block all these statutes. But Testoni says so far, courts have denied those requests and the laws have stayed in effect despite significant opposition advocacy by drugmakers. An increasing number of states also have enacted laws requiring 340B hospitals to report substantial data on their 340B costs and savings, and some are looking to limit how hospitals can use those savings.Resources:Senate Hearing Features Both Bipartisan Support for 340B and Calls for ReformsRead Our Comments on CBO's 340B Growth ReportReview Our 340B Rebate Pilot and IRA ResourcesBeacon Shares New Details on 340B Rebate Pilot Implementation

Joyce talks about the Heist at the Louvre and hiring based on DEI initiatives may have compromised security, Zohran Mamdani's beliefs and what it could mean for New Yorkers if he is elected, and healthcare and pharmaceutical practices where costs reflect value. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This week, I am joined by Celia from the Bay Area, California, who shares her journey from birthing with medical midwives and working as a doula, to stepping fully into sovereign birth work and choosing freebirth with her fourth child.Born at home herself, Celia's path was forever changed when she read Portal and began to unravel everything she thought she knew about birth. As a graduate of the Radical Birth Keeper School, she now carries this work forward in her own community.Celia reflects on her four births, including the painful memory of her midwife pulling out her placentas. She shares how, in her fourth and most recent birth, allowing her placenta to be born in her own way and her own time became her favorite part of the entire experience.In this conversation, Celia names what it means to let birth be simple, to trust herself, and to claim it all.✨ Join The Lighthouse — A private, life-changing membership space for conscious, sovereign women. Check it out here.✨Donate to the podcast here. If you want to connect with Celia, follow her on Instagram here and find her website here. Find more from Emilee on Instagram, YouTube and the Free Birth Society website.Disclaimer: Free Birth Society, LLC of North Carolina shares personal and educational stories and experiences related to freebirth and holistic care. This content is not medical advice, and we are not a licensed midwifery practice. Testimonials reflect individual experiences; results may vary. For services or scheduling, contact info@freebirthsociety.com. See full disclaimer at freebirthsociety.com/youtubeterms.

Label changes for tranexamic acid; new approval for Tezspire; psychedelic gains Breakthrough Tx for depression; oral semaglutide approved to reduce MACE risk in T2DM; Gazyva approved for lupus.

“It wasn't a profession, it was a way of life,” observes internationally respected psychiatrist Dr. Nasser Loza, reflecting on a century-long family legacy in mental health care that began when his grandfather founded The Behman Hospital in Cairo. In this candid Raise the Line conversation with host Michael Carrese, Dr. Loza traces the transformation of psychiatry he's witnessed in his long career as increases in classifications, payment bureaucracy, reliance on pharmaceuticals, and technological disruption have each left their mark. The cumulative costs associated with these changes have, he laments, pushed care out of reach for many and hindered the human connection that is key to the discipline. He describes his prescription for countering these trends as a focus on effective and modest aims. “Rather than saying, come and see me in therapy for five years and I will make a better person out of you, I think focusing on symptom-targeted help is going to be what is needed.”  In this wide-ranging interview, you'll also learn about progress on advancing the rights of mental health patients and lowering stigmas, how to manage the rise of online therapy and use of AI chatbots, and the importance of empathy and transparency in mental health counseling. Don't miss this valuable perspective on a critically important dimension of healthcare that's informed by decades of experience as a clinician, government official and global advocate. Mentioned in this episode:The Behman HospitalMaadi Psychology Center If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Seaford President Tamara Seales discusses navigating Canadian pharma regulations, team-building, and weaving DEI into the fabric of the company. Get full access to NPC Healthbiz Weekly at healthbiz.substack.com/subscribe

Sally Wolf is back in the studio and this time we left cancer at the door. She turned 50, brought a 1993 Newsday valedictorian article as a prop, and sat down with me for a half hour of pure Gen X therapy. We dug into VHS tracking, Red Dawn paranoia, Michael J. Fox, Bette Midler, and how growing up with no helmets and playgrounds built over concrete somehow didn't kill us.We laughed about being Jewish kids in the suburbs, the crushes we had on thirty-year-olds playing teenagers, and what it means to hit 50 with your humor intact. This episode is part nostalgia trip, part roast of our own generation, and part meditation on the privilege of being alive long enough to look back at it all. If you ever watched Different Strokes “very special episodes” or had a Family Ties lunchbox, this one's for you.RELATED LINKSSally Wolf Official WebsiteSally Wolf on LinkedInSally Wolf on InstagramCosmopolitan Essay: “What It's Like to Have the ‘Good' Cancer”Oprah Daily: “Five Things I Wish Everyone Understood About My Metastatic Breast Cancer Diagnosis”Allure Breast Cancer Photo ShootTom Wilson's “Stop Asking Me the Question” SongFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

“When I was in medical school, no one had even heard of mitochondrial disease. Today, every student who graduates here knows what it is and has seen a patient with it,” says Dr. Mary Kay Koenig, director of the Center for the Treatment of Pediatric Neurodegenerative Disease at UTHealth Houston McGovern Medical School. That remarkable change in awareness has been accompanied by advances in genetic sequencing, the development of clinical guidelines, and the emergence of potential treatments in some forms of mitochondrial disease. In fact, Dr. Koenig's multidisciplinary team at UTHealth's Mitochondrial Center of Excellence has been a key player in clinical trials that may yield the first FDA-approved treatments for it. As you'll learn in this Year of the Zebra conversation with host Michael Carrese, her work in neurodegenerative diseases also includes tuberous sclerosis, where advanced therapies have replaced the need for repeated surgeries, and Leigh Syndrome, which has seen improvements in diagnoses and supportive therapies leading to better quality of life for patients.  Tune in as Dr. Koenig reflects on an era of progress in the space, the rewards of balancing research, teaching and patient care, and the need for more clinicians to center listening, humility and honesty in their approach to caring for rare disease patients and their  families.Mentioned in this episode:Mitochondrial Center of ExcellenceCenter for the Treatment of Pediatric Neurodegenerative Disease If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

What's really hiding in your tap water? In this eye-opening episode of Wholistic Living, we dive deep into what North Americans are actually drinking ! From microplastics leaching out of PEX pipes to hormones, pharmaceuticals, pesticides, and heavy metals that slip through outdated filtration systems. You'll learn how estrogen residues from medications are causing fish to become intersex, why fluoride and chlorine byproducts are linked to thyroid and reproductive issues, and how mold and mycotoxins can contaminate your water supply without ever being tested for. Marla breaks down the truth about “safe” water regulations, the hidden toxins that burden your detox pathways, and the simple at-home filtration upgrades that protect your family's health. Whether you're dealing with autoimmune symptoms, hormone imbalance, or just want to support your body's natural detox, this episode will change how you look at the water coming out of your faucet. Join the 60 Day Gut Reset & Start When You're ready with $200 OFF! https://checkout.teachable.com/secure/1716725/checkout/order_4mzzdrn3?coupon_code=SECRETOFFEREquip Foods Grass-fed beef protein - Code: MARLAWant to work with me? email me to health@holisticspring.com

Are we being misled by the modern healthcare system? In this eye-opening conversation, Dr. Joe Jacko—author of Bamboozled, Duped & Hoodwinked—reveals the hidden truths behind modern medicine, pharmaceutical influence, and why chronic disease care often misses the root cause. 

After surviving domestic violence and a series of traumatic hospital births, Tahlia from Australia made the courageous decision to leave her abusive partner and begin again.In rebuilding her life, she came to understand what it truly means to make herself available to health, love, and sovereignty.That path culminated in the extraordinary experience of birthing her twins at home—on her terms, in her power.This conversation is a testament to resilience, reclamation, and the deep transformation that becomes possible when a woman chooses herself.✨ Get Our *Free* Freebirth Starter Kit - Just getting started? Download our powerful, free starter kit to begin your journey with clarity and support.Download here. ✨Donate to the podcast here.If you want to connect with Tahlia, follow her on Instagram here. Find more from Emilee on Instagram, YouTube and the Free Birth Society website.Disclaimer: Free Birth Society, LLC of North Carolina shares personal and educational stories and experiences related to freebirth and holistic care. This content is not medical advice, and we are not a licensed midwifery practice. Testimonials reflect individual experiences; results may vary. For services or scheduling, contact info@freebirthsociety.com. See full disclaimer at freebirthsociety.com/youtubeterms.

Dr. Nikki Maphis didn't just lose a grant. She lost a lifeline. An early-career Alzheimer's researcher driven by her grandmother's diagnosis, Nikki poured years into her work—only to watch it vanish when the NIH's MOSAIC program got axed overnight. Her application wasn't rejected. It was deleted. No feedback. No score. Just gone.In this episode, Oliver Bogler pulls back the curtain on what happens when politics and science collide and promising scientists get crushed in the crossfire. Nikki shares how she's fighting to stay in the field, teaching the next generation, and rewriting her grant for a world where even the word “diversity” can get you blacklisted. The conversation is raw, human, and maddening—a reminder that the real “war on science” doesn't happen in labs. It happens in inboxes.RELATED LINKS:• Dr. Nikki Maphis LinkedIn page• Dr. Nikki Maphis' page at the University of New Mexico• Vanguard News Group coverage• Nature article• PNAS: Contribution of NIH funding to new drug approvals 2010–2016FEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, visit outofpatients.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

“Giving learners options gives them a better learning experience. It's more holistic and more comprehensive,” says Sean Moloney, CEO and founder of EmbodyXR, an extended reality platform focused on the use of immersive technologies in medical education. In this eye-opening Raise the Line conversation, Moloney explains how AI-powered extended reality (XR) --which integrates augmented, virtual, and simulation-based environments -- allows learners to interact with patients, explore multiple diagnostic choices, and experience varied outcomes based on their decisions. The result, he notes, is not only stronger engagement in learning, but a measurable improvement in understanding. Despite these gains, Moloney is quick to point out that he sees these technologies as complements to traditional training, not substitutes for it. “We'll never replace in-person teaching,” he says, “but we can make learners even better.” Beyond training future clinicians, the EmbodyXR platform is also offering new modes of patient and caregiver education, such as augmented reality guidance for using medical devices at home. Join host Lindsey Smith as she explores how EmbodyXR achieves and maintains clinical accuracy, the connectivity it offers between headsets, personal computers and mobile devices, and other capabilities that are shaping the future of how healthcare professionals and patients will learn. Mentioned in this episode:EmbodyXR If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Ep. #120Topics:- Alternatives for panadol & why Dan doesn't give her sons pharmaceuticals - Dans journey & perspectives with co-sleeping- Are home births safer than hospital births? - Navigating conversations around how you are wanting to birth your child- Homeopathy - Lotus births - Why do parents invest in the wrong things?+ more!Listen to Dans podcast ⁠here⁠Work with Dan ⁠here⁠Apply for 1:1 health coaching with Lil ⁠⁠here ⁠⁠Follow the WWSK Instagram ⁠⁠⁠⁠⁠⁠⁠⁠⁠here⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  ⁠⁠⁠⁠⁠⁠⁠⁠⁠and Heal With Lil Instagram ⁠⁠⁠⁠⁠⁠⁠⁠⁠here⁠⁠⁠⁠⁠⁠⁠⁠Disclaimer - This podcast is for educational and entertainment purposes only and does not substitute for professional medical advice. Please always consult with a medical practitioner when seeking medical advice.

Carla Tardiff has spent 17 years as the CEO of Family Reach, a nonprofit that shouldn't have to exist but absolutely does—because in America, cancer comes with a price tag your insurance doesn't cover.We talk about shame, fear, burnout, Wegmans, Syracuse, celebrity telethons, and the godforsaken reality of choosing between food and treatment. Carla's a lifer in this fight, holding the line between humanity and bureaucracy, between data and decency. She's also sharp as hell, deeply funny, and more purpose-driven than half of Congress on a good day.This episode is about the work no one wants to do, the stuff no one wants to say, and why staying angry might be the only way to stay sane.Come for the laughs. Stay for the rage. And find out why Family Reach is the only adult in the room.RELATED LINKSFamily ReachFinancial Resource CenterCarla on LinkedInMorgridge Foundation ProfileAuthority Magazine InterviewSyracuse University FeatureFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Why has America struggled so much to effectively manage the opioid use crisis? One of the answers, as you'll learn in this eye-opening episode of Raise the Line, is rooted in laws and attitudes from the early 20th century that removed addiction from the realm of medicine and defined it as a moral failing.  “The federal Harrison Act of 1914 forbade any physician from prescribing opioids to people with addiction, so it became more the purview of law enforcement or behavioral health or religion,” says Dr. Melody Glenn, who regularly confronts the consequences of this history during shifts in the emergency department at Banner-University Medical Center in Tucson, Arizona. And as Glenn explains to host Caleb Furnas, the resulting stigma associated with addiction has extended to the treatments for it as well, especially methadone, despite its effectiveness. Drawing on her dual expertise in emergency and addiction medicine, Glenn dispels misconceptions that medication-assisted treatment merely replaces one addiction with another, and emphasizes that harm reduction is critical to saving lives. Her desire to break prevailing stigmas led her to discover the story of Dr. Marie Nyswander, who pioneered methadone maintenance therapy in the 1960s and is featured in Dr. Glenn's new book, Mother of Methadone: A Doctor's Quest, a Forgotten History, and a Modern-Day Crisis. You'll leave this instructive interview understanding the roots of our flawed approach to addiction treatment, meeting an overlooked pioneer in the field, and admiring a devoted and compassionate physician who is following in her footsteps.  Mentioned in this episode:Banner-University Medical CenterMother of Methadone book If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

About this episode: Buprenorphine is a highly effective medication used for treating opioid use disorder. But accessing this lifesaving prescription can be challenging. In this episode: Jeff Hom and Marlene Lira talk about the critical role of buprenorphine in reducing overdose deaths and the role pharmacies can play in improving access. Guests: Jeff Hom, MD, MPH, is the Medical Officer for Science and Policy in the Substance Use Services section of the San Francisco Department of Public Health. He is also a DrPH student in Health Policy and Bloomberg Fellow at the Johns Hopkins Bloomberg School of Public Health. Marlene C. Lira, MPH, is the Senior Director of Research at Workit Health, a multi-state telemedicine treatment provider for evidence-based addiction care, and a doctoral candidate in Health Policy & Management at the Johns Hopkins Bloomberg School of Public Health. Host: Lindsay Smith Rogers, MA, is the producer of the Public Health On Call podcast, an editor for Expert Insights, and the director of content strategy for the Johns Hopkins Bloomberg School of Public Health. Show links and related content: Pharmacy Barriers to Receiving Buprenorphine Among Patients Undergoing Telemedicine Addiction Treatment—JAMA Network Open Prescribing Buprenorphine By Telehealth: Lessons From San Francisco Amidst A Changing Regulatory Landscape—Health Affairs The New Federal Regulations Aimed Making Methadone More Accessible—And Less Stigmatizing—Public Health On Call (April 2024) Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌JohnsHopkinsSPH on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.

About two years ago, Indiana University Health implemented a 340B-funded comprehensive medication review clinic after pharmacy staff noticed patients at their hospitals were not filling maintenance prescriptions due to high cost. Although patient assistance was available, there was not a systematic approach to connecting qualifying patients with the financial help and education they needed, and the health system started the clinic to fill that gap. IU Health Regional Pharmacy Manager of Ambulatory Services Carrie Krekeler discusses how the clinic came about and how it works to improve patient health outcomes.Improved Drug Affordability and Patient EducationWhen a prescription goes through IU Health's comprehensive medication review clinic, pharmacists and other staff will prioritize finding financial assistance for eligible individuals and teaching patients important information about taking their medications. Krekeler says clinic staff will look for discounts for all medications a patient is on and see what a patient's insurance will cover, if there are copays, and if prior authorization is needed. Staff then will connect patients to coupon cards, manufacturer assistance programs, or 340B-funded assistance through IU Health.Demonstrated ResultsIn the two years since the clinic launched, Krekeler says its success has prompted IU Health to reinvest more 340B dollars to expand its reach. Patients with heart failure and diabetes who have gone through the clinic have seen significant improvements in their key health metrics. The clinic helps patients better maintain their health and stay out of the hospital.Understanding 340B Is Vital for Such ProgramsKrekeler says IU Health was able to launch its clinic after adapting a similar initiative that UC Davis had implemented. The key to getting the IU Health clinic off the ground was obtaining buy-in from executives who understood 340B and finance and were able to see the long-term benefit in investing 340B dollars in this area.

This week on the Free Birth Society Podcast, I sit down with homeopath Melissa Kupsch for a rich and fascinating dive into the world of homeopathy.We explore its powerful history, reaching back to the days when homeopathy was a dominant and respected medicine. Melissa shares the almost unbelievable personal story that awakened her to this path, and she offers a mountain of wisdom and practical guidance for anyone curious about where to begin.This conversation is equal parts history, testimony, and initiation. If you've ever wondered about homeopathy—or sensed there is a whole realm of healing outside the medical model yet to be touched—this episode is a potent place to start.✨Are you a sovereign birth professional and want to be listed? Or would you like to connect to sovereign birth professionals near you? Visit Matribirthdirectory.com.✨Donate to the podcast here. If you want to connect with Melissa, follow her on Instagram here and you can find her website here.Find more from Emilee on Instagram, YouTube and the Free Birth Society website.Disclaimer: Free Birth Society, LLC of North Carolina shares personal and educational stories and experiences related to freebirth and holistic care. This content is not medical advice, and we are not a licensed midwifery practice. Testimonials reflect individual experiences; results may vary. For services or scheduling, contact info@freebirthsociety.com. See full disclaimer at freebirthsociety.com/youtubeterms.

What happens when science and spirit meet in the realm of medicine? In this episode, we sit down with Dr. Kristin Speer, PharmD, co-founder of the Psychedelic Pharmacists Association, to explore the future of safe, informed, and balanced use of psilocybin. She shares her groundbreaking work, including the development of the Psilocybin Interaction Checker, which helps identify and manage potential interactions between psilocybin and medications. From tapering strategies and harm reduction to microdosing and right-sizing medication profiles, this conversation is packed with insights on how psychedelics and traditional medicine can coexist safely and effectively.You can find show notes, resources and more at: https://tinyurl.com/4bdt2b6b  Are you called to serve the healing of our world? Join our microdosing facilitator program! You'll learn everything you need to know to become a resourced, skilled, and confident microdosing guide.Visit microdosingforhealing.com/professionaltraining

“We don't view a person with chronic pain as someone who has a chronic illness and the effect of that is we can't follow patients continuously over prolonged periods of time,” says Dr. Jacob Hascalovici, a neurologist and pain specialist based in New York City.  In co-founding Bliss Health, Dr. Jacob, as he is known, has set out to create a continuous care model for chronic pain treatment that matches the approach taken for patients with diabetes or high blood pressure. The Bliss Health formula includes an initial meeting with a physician that produces a care plan; remote therapeutic monitoring on an ongoing basis; and a monthly meeting with a nurse to review data and determine next steps, including additional appointments with physicians as needed.  All of this occurs via a digital platform which provides a welcome option for patients with mobility issues and can fill gaps in access to specialists, especially in rural areas. Dr. Jacob is also hoping to make chronic pain patents feel respected, which is not always the case in their encounters with the healthcare system. “Because pain is not something that can be seen or measured, oftentimes patients feel marginalized, dismissed and disempowered by providers.” Join Raise the Line host Lindsey Smith for a valuable conversation that also touches on policy changes that could strengthen telemedicine, and has details on the first non-opioid based pain medication to receive FDA approval in over 20 years.Mentioned in this episode:Bliss Health If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

How to trade and invest in the biotech space with ROTY Biotech Community's Jonathan Faison (0:35). Making money in biotech (5:40). Managing sector risk (9:20). Geron - a stock he never thought he'd own (17:10).Show Notes:Finding Winners In Biotech, Probably The Riskiest SectorSyndax Pharmaceuticals: A Tale Of Two Drug LaunchesArcutis Biotherapeutics: Another Approval Under Their BeltEpisode transcriptsFor full access to analyst ratings, stock and ETF quant scores, and dividend grades, subscribe to Seeking Alpha Premium at seekingalpha.com/subscriptions

In this episode of the Pain and Performance Podcast, I sit down with Dr. Joe Nussma, a toxicologist with nearly four decades of experience studying how chemicals, mold, and pharmaceuticals affect the human body.We unpack how chronic exposure to toxins can silently undermine your health, why mold exposure is often missed as the root cause of fatigue and inflammation, and what you can actually do to defend your body. Dr. Joe shares his insights on detoxification, water and air quality, and how powerful antioxidants like Carbon 60 may help the body recover from long-term exposure.This conversation will give you a framework for protecting yourself from everyday toxins and making smarter choices for lasting health.Key Takeaways-- Chronic low-level toxin exposure can overwhelm your body's defenses and drive long-term disease.-- Mold exposure often leads to fatigue, brain fog, and respiratory issues that go undiagnosed.-- Clean water and air are some of the simplest, most overlooked ways to reduce toxin load.-- Pharmaceuticals carry risks — multiple prescriptions (polypharmacy) can interact in harmful ways.-- Detoxification through nutrition, lifestyle, and antioxidants helps clear built-up toxins.-- Carbon 60 shows promise as a powerful antioxidant against oxidative stress.-- Stress itself acts like a toxin and can shorten lifespan if not managed.-- Small lifestyle improvements — in food, environment, and daily habits — compound into major health gains.Links: DERRICKTikTok:https://www.tiktok.com/@drderrickInstagram:https://www.instagram.com/derrickbhines/Youtube:https://www.youtube.com/@DrDerrickJOELinedIn: https://www.linkedin.com/in/joe-nieusma-1a72b81Website:https://www.superiortoxicology.com/

Jennifer J. Brown is a scientist, a writer, and a mother who never got the luxury of separating those roles. Her memoir When the Baby Is Not OK: Hopes & Genes is a punch to the gut of polite society and a medical system that expects parents to smile through trauma. She wrote it because she had to. Because the people who gave her the diagnosis didn't give her the truth. Because a Harvard-educated geneticist with two daughters born with PKU still couldn't get a straight answer from the very system she trained in.We sat down in the studio to talk about the unbearable loneliness of rare disease parenting, the disconnect between medical knowledge and human connection, and what it means to weaponize science against silence. She talks about bias in the NICU, the failure of healthcare communication, and why “resilience” is a lazy word. Her daughters are grown now. One's a playwright. One's an artist. And Jennifer is still raising hell.This is a conversation about control, trauma, survival, and rewriting the script when the world hands you someone else's lines.Bring tissues. Then bring receipts.RELATED LINKS• When the Baby Is Not OK (Book)• Jennifer's Website• Jennifer on LinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, visit outofpatients.show.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In recent months, public health advocates in the United States have raised concerns about proposed changes to vaccine policy, cuts to food assistance programs, rollbacks of environmental protections and reductions in public health staffing. Chief among them has been Dr. Georges Benjamin who, as executive director of the American Public Health Association (APHA) since 2002, has led national efforts to create a healthier America. Raise the Line host Lindsey Smith recently sat down with Dr. Benjamin to understand more about the current state of public health and explore the path forward, and learned that a top priority for APHA is battling the misinformation that Dr. Benjamin believes is fueling support for many of these changes. “The challenge we have right now is that as a society, we've gone into our little corners and live in our own ecosystems. More people are getting their information from a single source and they're not validating that information to make sure that it's true.” Tune into this thoughtful and timely conversation to hear Dr. Benjamin's advice for curbing the spread of misinformation, how APHA is trying to help people understand the value of public health initiatives, and what the U.S. can learn from other countries about improving public health. Mentioned in this episode:American Public Health Association If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

New treatment approved for primary humoral immunodeficiency; eyedrops now available to improve near vision; Tremfya approval expanded to include pediatric plaque psoriasis, psoriatic arthritis; FDA fast tracks treatments for methamphetamine intoxication, Alzheimer disease.

This episode of Standard Deviation features Oliver Bogler in conversation with Dr Na Zhao, a cancer biologist caught in the crossfire of science, politics, and survival. Na's life reads like a brutal lab experiment in persistence.She grew up in China, lost her mother and aunt to breast cancer before she turned twelve, then came to the United States to chase science as both an immigrant and a survivor's daughter. She worked two decades to reach the brink of independence as a cancer researcher, only to watch offers and grants vanish in the political chaos of 2025.Oliver brings her story into sharp focus, tracing the impossible climb toward a tenure-track position and the human cost of a system that pulls the ladder up just as people like Na reach for it. This conversation pulls back the curtain on the NIH funding crisis, the toll on early-career scientists, and what happens when personal tragedy fuels professional ambition.Listeners will walk away with a raw sense of how fragile the future of cancer research really is, and why people like Na refuse to stop climbing.RELATED LINKSDr Zhao at Baylor College of MedicineDr Zhao on LinkedInDr Zhao's Science articleIndirect Costs explained by US CongressFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

“Probably the most exciting thing I've seen in gene therapy over the last ten years is we now have a lot of tools for selective delivery, which will hopefully make treatments more safe and a lot more successful,” says Dr. Jessica Duis, a geneticist and pediatrician focused on the management of individuals with complex, rare disorders. Dr. Duis, who has worked on several gene therapies that are now approved or progressing through the accelerated approval pathway, is currently VP of Clinical Development at GondolaBio, a clinical-stage biopharmaceutical company focused on developing therapeutics for genetic diseases. As you'll learn in this Year of the Zebra episode with host Lindsey Smith, Dr. Duis is encouraged by other recent advances in genetic technology as well, and thinks momentum will grow as breakthrough treatments emerge. “I think we're hopefully going to continue to see companies that are working in rare disease be more successful and really drive how regulators think about making decisions in terms of bringing treatments to patients. I think we're at the tip of the iceberg in terms of the future of truly transformational therapies.”  This wide ranging conversation also explores Dr. Duis' team approach to patient care, her work on clinical endpoints, the importance of patient communities, and her book series, Rare Siblings Stories.Mentioned in this episode:GondolaBioRareDiseaseDocElsevier Healthcare Hub on Rare DiseasesRare Sibling Stories If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Katie Henry has seen some things. From nonprofit bootstraps to Big Pharma boardrooms, she's been inside the machine—and still believes we can fix it. We go deep on her winding road from folding sweaters at J.Crew to launching a vibrator-based advocacy campaign that accidentally changed the sexual health narrative in breast cancer.Katie doesn't pull punches. She's a born problem solver with zero tolerance for pink fluff and performative empathy. We talk survivor semantics, band camp trauma, nonprofit burnout, and why “Didi” is the grandparent alter ego you never saw coming.She's Murphy Brown with a marimba. Veronica Sawyer in pharma. Carla Tortelli with an oncology Rolodex. And she still calls herself a learner.This is one of the most honest, hilarious, and refreshingly real conversations I've had. Period.RELATED LINKS:Katie Henry on LinkedInKatie Henry on ResearchGateLiving Beyond Breast CancerNational Breast Cancer CoalitionFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Four leading physicians from the Healing for the A.G.E.S. community—Dr. Bryan Ardis, Dr. Edward Group III, Dr. Henry Ealy, and Dr. Jana Schmidt—come together to explore cutting-edge, nature-based healing strategies for modern health challenges. Drawing on their collective expertise in naturopathy, detoxification, environmental medicine, and holistic wellness, they discuss how to counteract threats like EMFs, nanotechnology, and “weaponized biology,” while restoring the body's innate healing capacities. The conversation blends scientific insight, spiritual perspective, and practical protocols to empower listeners to reclaim control over their health. Stop being a patient and start being student. Join the A.G.E.S. community of healers today! https://HealingForTheAges.com ___________________You can take advantage of one of the best holistic health conferences anywhere and enter Discount Promo Code – GRIT for 30% off all My EHI Aloha courses and Healing for the A.G.E.S. events and replays by visiting https://myehialoha.org/#GRIT--------------------------Check out all of our vendors at: https://patriotswithgrit.com/patriot-partners/ SPONSORS FOR THIS VIDEO❤️ Cardio Miracle – One Drink. Endless Benefits.Feel steady energy, sharper clarity, and stronger resilience every day.Own your freedom in health & experience the full power your body was designed for.